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INTRODUCTION
Fluorescein dye was initially synthesized by Adolf von Baeyer in 1871(1).
Novotny and Alvis developed a photographic system for sequential
documentation of fluorescein flow through the ocular fundus in 1960(2).
Fluorescein angiography is a diagnostic technique used in the inter-
pretation of ocular pathologic states. It allows sequential visualization of
blood flow simultaneously through retinal, choroidal and iris tissues(3). In
wide use for over 40 years, it is a valuable tool in the study, the understan-
ding, and the treatment of ocular diseases(3-4).
This is considered a relatively safe procedure, although numerous ad-
verse reactions have been reported in the literature. These are divided into
mild (nausea, vomiting, pruritus, sneezing, vaso-vagal disorders, inadver-
tent arterial injection), moderate (urticaria, other skin eruptions, syncope,
thrombophlebitis, pyrexia, local tissue necrosis, muscular paralysis) and
severe (bronchospasm, laryngeal edema, circulatory shock, myocardial in-
farction, tonic-clonic seizure)(5-7).
Adverse reactions of fluorescein angiography:
a prospective study
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Purposes: To determine both the incidence of adverse reactions in
patients who underwent fluorescein angiography for the first time and to
determine whether systemic arterial hypertension, diabetes or allergy
history increases the chance of reaction to intravenous fluorescein.
Methods: Data collection was carried out between January 2001 and
October 2002 in Recife, Brazil. Patients with prior fluorescein angiography
history, pregnant patients or patients in use of corticosteroids, immuno-
suppressive or antihistamine drugs were excluded. Results: Out of 1,500
enrolled patients, 1,039 (69.3%) underwent the test for the first time. The
mean age was 58 ± 16 years and the median age was 60 years. Of these, 628
(60.4%) were women. Nausea occurred in 71 (6.83%) patients, vomiting in
14 (1.35%), urticaria in 11 (1.06%), bronchospasm in 4 (0.38%) and laryngeal
edema in 1 (0.01%). Five patients presented more than one adverse
reaction. Higher incidences of adverse reactions were observed in diabetic
patients [p<0.002, RR=1.80 (CI=1.24-2.60)], patients with systemic arterial
hypertension [p<0.002, RR=1.84 (CI=1.26-2.71)] and patients with allergy
history [p<0.001, RR=3.90 (CI=2.70-5.63)]. Conclusions: A cumulative
incidence of 9.72% adverse reactions was observed in patients who had
undergone this test for the first time. The presence of the allergy history,
diabetes or systemic arterial hypertension increased the incidence of
adverse reactions to the dye.
ABSTRACT
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Previous studies indicate that the most frequent adverse
reactions are mild, such as nauseas and vomiting (2% to 14%)
and that moderate and severe reactions are infrequent (<1%)(5-6,8).
The reported frequency of these adverse reactions has varied
among authors, however most of the studies are retrospective
and they do not distinguish patients who had previously
undergone this test from those who had undergone it for the
first time(7,9-10).
The exact mechanism of adverse reactions in fluorescein
angiography is not clearly understood. Some proposed me-
chanisms include: histamine release of non-allergic nature in
the absence of antigen-antibody reaction (anaphylactoid
reactions); vaso-vagal phenomenon resulting in bradycardia,
arterial hypotension and reduced cardiovascular perfusion;
drug allergy of the immediate hypersensitivity type (anaphy-
lactic reactions); anxiety-related medullary sympathetic dis-
charge, eliciting tachycardia and myocardial stress; direct
vasospastic toxic effect of intravenous injection; effect of
contamination during manufacture of the drug; direct syste-
mic effect of topical mydriatics, particularly phenylephrine; or
any combination of the above potential factors(7).
Retinal complications of hypertensive and diabetic retino-
pathy are the main diseases that motivate request for this
test(11-12). Some authors report that allergy history, systemic
arterial hypertension (SAH) and diabetes increase the risk of
adverse reactions to fluorescein injection(8-9).
The purposes of this prospective study are both to deter-
mine the incidence of adverse reactions in patients who had
undergone fluorescein angiography for the first time, and to
determine if SAH, diabetes or allergy history increase the
chance of reaction to intravenous fluorescein.
METHODS
Patients and medical procedures
The study was performed in Recife, Brazil. This eye clinic
has a demand predominantly consisting of private patients
from the metropolitan region of Recife, performing annually
900 fluorescein angiographies. It is a referral center for retina
diseases with two specialists.
Data collection was carried out between January 2001 and
October 2002 in Recife, Brazil. Patients with prior fluorescein
angiography history, pregnant patients or patients in use of
corticosteroids, immunosuppressive or antihistamine drugs
were excluded. The study was approved by the local ethics
committee and by the ethics committee of the Federal Univer-
sity of Pernambuco (CONEP number 0150.0.172.000-06). All
patients filled out a written consent.
Sodium fluorescein 20%® (Ophthalmos) was used in a
single 2.5 ml dose, injected into the cubital vein, with a manual
infusion speed of approximately 1 ml per second. The images
were caught through a Topcon Retinal Camera® 50 FX with the
aid of a digital program (Ophthalmic System Image).
Medical preoperative evaluation was performed one hour
before the test by an anesthesiologist. It consisted of anam-
nesis and physical examination. Twenty-two patients were
not allowed to undergo the angiogram because they presen-
ted a systemic arterial pressure higher than 160/110 mmHg.
Data Collection
Anamnesis and physical examination were collected on a
specific form completed by the anesthesiologist at the time of
the clinical examination. Adverse reactions that occurred du-
ring and after the angiography were registered in a standar-
dized form by the ophthalmologist.
The definitions of adverse reactions to fluorescein regis-
tered at this study were based on the literature(7). Local dye
leaking was not included among the adverse reactions for
being considered inherent to the application technique and
not a systemic clinical reaction to the dye. Reactions that
occurred up to 24 hours after dye injection were considered
related to the test. Twenty-four hours following eye clinic
discharge, all patients were asked by phone interview about
medical events within this period.
Patients considered with allergy history were those with a
report of anaphylactic or anaphylactoid reactions to specific
substances, individuals with bronchial asthma, allergic
rhinitis or urticaria. The definitions of SAH and diabetes were
those adopted in the literature(13).
Sample size and statistical analysis
A sample of 1,000 patients who were submitted to the
fluorescein angiography for the first time was planned. It was
assumed that 30% of the tests were in patients who had
previously undergone fluorescein angiography, and then a
total of 1,500 tests were performed during a period of one year
and nine months.
As parameters for central trend and dispersion for data,
mean, pattern deviation and median were determined. For ca-
tegorical variables, chi-square test, relative risk and confiden-
ce interval of 95% were calculated; for continuous variables,
Student’s t test was used. Results of these analyses were
considered statistically significant if P values were <0.05.
RESULTS
Of the 1,500 enrolled patients, 461 (30.7%) had already
undergone fluorescein angiography and 1,039 (69.3%) under-
went this test for the first time. Subsequent analyses of this
study mentioned the latter in an exclusive way.
The mean age was 58 ± 16 years and the median age was 60
years. Sixty hundred-twenty-eighty (60.4%) patients were fe-
male and 411 (39.6%) male. Four hundred ninety-two (47.3%)
patients had SAH, 376 (36.2%) diabetes and 211 (20.3%) an
allergy history.
The incidence of adverse reactions to the dye was 9.24%
(96 patients). Mild reactions occurred in 85 (8.18%) patients
[nauseas in 71 (6.83%) and vomiting in 14 (1.35%)], moderate
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reactions in 11 (1.06%) patients (urticaria) and severe reac-
tions in 5 (0.48%) patients [bronchospasm in 4 (0.38%) and
laryngeal edema in 1 (0.1%)]. The cumulative incidence of
adverse reactions was 9.72% (101 patients) because five sub-
jects presented more than one adverse reaction. Four patients
had urticaria and bronchospasm and one had urticaria and
laryngeal edema, all of which are considered anaphylactoid
reactions. No reaction occurred within the 24-hour period after
the patient had left the eye clinic.
The mean age of patients who presented reactions to
fluorescein was 57.2 ± 12.5 years and for those who had no
reaction it was of 59.0 ± 15.4 years (p<0.273). Among the
former, 56 (58.3%) were women, while among the latter, 572
(60.6%) were women (p<0.657).
A higher incidence of adverse reactions was observed in
patients with diabetes [p<0.002, RR=1.80 (CI=1.24-2.60)], SAH
[p<0.002, RR=1.84 (CI=1.26-2.71)] and allergy history [p<0.001,
RR=3.90 (CI=2.70-5.63)] (Table 1).
DISCUSSION
Almost all patients with ocular problems are exposed to
fluorescein, in topical form, during routine ocular examination.
However, the report of adverse reactions is rare. In case of oral
administration of fluorescein, the frequency of reactions is bet-
ween 1% and 2%(14-16) and in case of intravenous dye it is bet-
ween 3% and 20%(4-8,17-18). In this study, the cumulative incidence
of adverse reactions to dye injection was 9.72% in patients who
were submitted to fluorescein angiography for the first time.
Mild reactions as nausea and/or vomiting occurred in
8.18% of the patients. In other studies, they ranged from 3% to
14%(6,9,19-20). The pathophysiology of these effects involves
the activation of chemical receptors in the vomiting nervous
center located in the area postrema that function as primary
detectors of emetic stimulation and induce vomiting through
integration with vagal nerve or vestibular system(21).
Moderate and/or severe reactions as urticaria, bronchos-
pasm and laryngeal edema were infrequent, with incidences of
1.06%, 0.38% and 0.1%, respectively. Other authors report fre-
quencies of urticaria between 0.5% and 1.2%(6-7,10) and of respi-
ratory distress between 0.02% and 0.1%(7-8,19). Such reactions
can be explained by different pathophysiologic mechanisms;
however they are probably of the anaphylactoid type, cha-
racterized by independent IgE mechanisms that involve direct
activation of mast cells, activation of complement system and
alterations in arachidonic acid metabolism(22-23). Skin tests with
fluorescein have no predictive value and it is useless to perform
them since the reaction mechanism is not IgE-mediated, and
thus they reinforce the above described pathophysiology(24-25).
Death as result of the test was not observed in this study,
though it may occur very rarely. There are reports of one for
each 200,000 patients, but with controversies of the direct
relation to test performance(7,10,26-28).
Gender did not show itself as a statistically significant
factor for the presence of adverse reactions (p<0.657). Pa-
tients with SAH [p<0.002, RR=1.84 (CI=1.26-2.71)] or diabetes
[p<0.002, RR=1.80 (CI=1.24-2.60)] presented higher incidence
of adverse reactions, mainly of the mild type. There is no
definitive reason for this association; a presumable mecha-
nism is the predisposition of these groups to vaso-vagal reac-
tions because of neurovegetative system instability(7,9).
Patients with an allergy history [p<0.001, RR=3.90 (CI=2.70-
5.63)] also presented higher incidence of adverse reactions to
the test. Possibly this is due to the fact that atopic patients
have immunologic mechanisms in its etiopathophysiologies,
mainly reactions of the immediate hypersensitivity type(29).
A possible limitation of this study was the use of 25%
fluorescein, while some of the studies used 10% fluorescein.
However, in the literature, difference in the incidence or
severity of adverse reactions between 10% and 25% concen-
trations(7,30) was not observed.
CONCLUSIONS
A cumulative incidence of 9.72% of adverse reactions was
observed in patients who had undergone this test for the first
time. The presence of allergy history, diabetes or SAH increa-
sed the incidence of adverse reactions to the dye.
Table 1. Coexistent diseases and their correlation with the adverse reactions, Recife
Coexistent Adverse reactions
disease Mild Moderate Severe Relative risk
(N) Nausea Vomiting Urticaria Broncho- Laryngeal Total P  (95% CI) †
spasm edema
SAH (492) 45 9 8 0 1 63 0.002* 1.84 (1.26-2.71)
Without SAH (547) 26 5 3 4 0 38
Diabetes (376) 35 7 8 0 1 51 0.002* 1.80 (1.24-2.60)
Without Diabetes (663) 36 7 3 4 0 50
Allergy (115) 20 4 8 0 1 33 0.001* 3.90 (2.70-5.63)
Without Allergy (924) 51 10 3 4 0 68
SAH= systemic arterial hypertension
*=  Significance in accordance with chi-square test
†= the relative risk to have adverse reactions is for patients that had coexistent disease as compared with patients that did not have coexistent disease. CI denotes
confidence interval
70(4)11.p65 24/08/07, 18:23617
Arq Bras Oftalmol. 2007;70(4):615-8
618 Adverse reactions of fluorescein angiography: a prospective study
RESUMO
Objetivos: Determinar a incidência de reações adversas em
pacientes submetidos à angiofluoresceinografia pela primeira
vez e determinar se hipertensão arterial sistêmica, diabetes ou
história de alergia aumentam a chance de reações à fluoresceína
intravenosa. Métodos: Os dados foram coletados entre janeiro
de 2001 e outubro de 2002 em Recife, Brasil. Pacientes com
angiofluoresceinografia prévia, gestantes ou pacientes em uso
de medicamentos corticosteróides, imunossupressores ou anti-
histamínicos foram excluídos. Resultados: Dos 1.500 pacientes
iniciais, 1.039 (69,3%) realizavam o exame pela primeira vez. A
idade média foi de 58 ± 16 anos e a mediana de 60 anos. Dentre
esses, 628 (60,4%) pessoas eram do sexo feminino. Náusea
ocorreu em 71 (6,83%) pacientes, vômito em 14 (1,35%), urticária
em 11 (1,06%), broncoespasmo em 4 (0,38%) e edema de laringe
em 1 (0,01%). Cinco pacientes apresentaram mais de uma reação
adversa. Maiores incidências de reações adversas foram obser-
vadas em diabéticos [p<0,002, RR=1,80 (IC=1,24-2,60)], hiper-
tensos [p<0,002, RR=1,84 (IC=1,26-2,71)] e pacientes com histó-
ria de alergia [p<0,001, RR=3,90 (IC=2,70-5,63)]. Conclusões:
Uma incidência cumulativa de 9,72% de reações adversas foi
observada em pacientes submetidos à angiofluoresceinografia
pela primeira vez. Presença de história de alergia, diabetes ou
hipertensão arterial aumentou a incidência de reações adversas
ao contraste.
Descritores: Angiofluoresceinografia; Anafilaxia; Hipersen-
sibilidade a medicamentos; Reações adversas
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